Dubermatinib
- Generic Name
- Dubermatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O2S
- CAS Number
- 1341200-45-0
- Unique Ingredient Identifier
- 14D65TV20J
- Background
Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
Early Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 3
- Registration Number
- NCT04518345
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Phase 1
Terminated
- Conditions
- Chronic Lymphocytic LeukemiaSLLSmall Lymphocytic LymphomaCLL
- Interventions
- Combination Product: TP-0903 and ibrutinib combination therapy
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03572634
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Duke University, Durham, North Carolina, United States
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Recurrent Ovarian CarcinomaColorectal CarcinomaBRAF-Mutated MelanomaAdvanced Solid TumorsEGFR Positive Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT02729298
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸US Oncology - Texas Oncology - Fort Worth, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath